# UNIVERSITY OF BIRMINGHAM

# University of Birmingham Research at Birmingham

# Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease

Clarke, Carl E; Patel, Smitaa; Ives, Natalie; Rick, Caroline E; Dowling, Francis; Woolley, Rebecca; Wheatley, Keith; Walker, Marion F; Sackley, Catherine M; PD REHAB Collaborative Group

DOI:

10.1001/jamaneurol.2015.4452

License:

None: All rights reserved

Document Version
Peer reviewed version

Citation for published version (Harvard):

Clarke, CE, Patel, S, Ives, N, Rick, CE, Dowling, F, Woolley, R, Wheatley, K, Walker, MF, Sackley, CM & PD REHAB Collaborative Group 2016, 'Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease: a randomized clinical trial', *JAMA Neurology*, vol. 73, no. 3, pp. 291-299. https://doi.org/10.1001/jamaneurol.2015.4452

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- •Users may freely distribute the URL that is used to identify this publication.
- •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- •User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
  •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 09. Apr. 2024

#### Randomised (N = 762)

#### Allocated to PT/OT (N=381)†

- Started PT/OT within 3 months of randomisation: n=353 (93%)
- Did not receive PT/OT within 3 months of randomisation: r=25 (6%)<sup>Ω</sup>
  - Started PT/OT after 3 months (r=12)
  - Never received PT/OT (n=13)
- Unknown whether patient has received PT/OT as therapy logs not returned: r=3 (1%)

#### 3 months NEADL data available for analysis: n=350 (/381; 92%)

- Form expected, but not returned (n=23)
- Form not expected (n=8)
  - Withdrawn (r=2)
  - Partially Withdrawn\* (n=5)
  - Died (r=1): Respiratory

# 9 months NEADL data available for analysis: n=326 (/373; 87%)

- Form expected, but not returned (r=41)
- Form not expected (n=6)
  - Partially Withdrawn\* (n=3)
  - Died (r=3): Cancer, Respiratory, Road traffic

## 15 months NEADL data available for analysis: n=311 (/367; 85%)

- Form expected, but not returned (r=45)
- Form not expected (n=11)
  - Withdrawn (r=3)
  - Partially Withdrawn\* (n=4)
  - Died (n=4): Cancer, Cardiovascular, Respiratory, Falls/Fracture

#### Allocated to no therapy $(N=381)^{++}$

- Received no therapy within 3 months of randomisation: n=372 (98%)
- Crossed over to PT/OT within 3 months of randomisation: n=9 (2%) !
  - Reasons for cross-over included worsening PD symptoms, falls and balance problems

### 3 months NEADL data available for analysis: n=349 (/381; 92%)

- Form expected, but not returned (n=27)
- Form not expected (n=5)
  - Withdrawn (n=2)
  - Partially Withdrawn\* (r=1)
  - Died (r=2): Cardiovascular, Natural causes

### 9 months NEADL data available for analysis: n=331 (/376; 88%)

- Form expected, but not returned (n=33)
- Form not expected (r=12)
  - Withdrawn (r=1)
  - Partially Withdrawn\* (n=2)
  - Died (n=9): Cancer, Cardiovascular, Respiratory, Infection

### 15 months NEADL data available for analysis: n=322 (/364; 88%)

- Form expected, but not returned (n=36)
- Form not expected (n=6)
  - Partially Withdrawn\* (r=2)
  - Died (n=4): Cancer, Cardiovascular, Respiratory

<sup>†</sup> Eight patients randomised to the PT and OT group were later found to be ineligible as they had received PT and/or OT for PD in the 12 months prior to randomisation (exclusion criteria). One patient did not receive any PT or OT post-randomisation (cross-over, only baseline data available - diagnosed with cancer and died at 5 months post-randomisation). One patient did not receive PT or OT within 3 months, but was referred for PT outside of the trial at 6 months (3, 9 and 15 month data available). The other six patients all received PT and/or OT post-randomisation (baseline and 3 month data available, except for one patient where only baseline data are available).

<sup>&</sup>lt;sup>††</sup> Three patients randomised to the no therapy group were subsequently found to be ineligible as they had received PT and/or OT for PD in the 12 months prior to randomisation (exclusion criteria). One patient received PT and/or OT within 3 months of randomisation (cross-over). For all three patients, baseline and 3 month data was available.

Thirteen patients randomised to the PT and OT group are known to have not received any PT or OT. Baseline and 3 month data are available for two of these patients (for the other eleven patients' only baseline data are available). Twelve patients did not receive PT or OT by 3 months post-randomisation, but did start therapy after 3 months; baseline and 3 month data are available for all patients (except two, one had baseline only and one has 3 month only).

<sup>!</sup> Nine patients randomised to no therapy had some PT and/or OT before their 3 month NEADL form was completed, all patients had baseline and 3 month data available.
\* Partially withdrawn patients did not wish to complete patient forms, but agreed to clinical follow-up